× Industry Reports Services Press Release Contact us About us

Asia Pacific Cell Line Development Market to hit $1.9 bn by 2024

 Request a sample

According to the Graphical Research new growth forecast report titled “Asia Pacific Cell Line Development Market analysis based on Product, Source, Cell Line, Application, Regional Outlook - Industry Size, Share, Growth Trends & Forecast, 2018 – 2024, Estimated to Exceed USD 1.9 billion By 2024

Increasing prevalence of cancer in the region is the key factor that will drive Asia Pacific cell line development market growth. India has third highest number of cancer cases among women, after China. Growing adoption of vaccines and monoclonal antibodies in treatment of cancer and other chronic disease will fuel the demand for cell line cultures thereby augmenting cell line development business growth.

Advancement in cell line development techniques is another positive impact rendering factor in cell line development market growth. Availability of advanced methods to enable faster and higher production of cell lines will contribute to industry growth. However, issues related to stem cell research and complex regulatory scenario might impede the cell line development market growth over the analysis period.

Reagents and media product segment dominated the market with 53.8% revenue share in 2017 and is projected to show robust growth during the forthcoming period. Reagents and media are widely used in drug discovery, tissue engineering and other research applications. Rising demand for biological buffers, freezing reagents and dissociation reagents for research purpose will foster segmental growth over the analysis period.

Hybridomas was the second largest cell line type segment in 2017. The market is expected to show lucrative CAGR of 14.2% over the forecast period due to advantages associated with it such as ability to grow continuously, combination of two different types of cells, and production of pure antibodies on a large-scale.

Bioproduction application segment accounted for USD 347.0 million in 2017 and will witness significant growth during the forthcoming years. Advent of rDNA technology has drastically increased the demand for biological products for disease treatment. Wide adoption of advanced technologies in production of monoclonal antibodies, peptides, therapeutic hormones and other biological products will stimulate bioproduction segment growth.

Japan cell line development market dominated the Asia Pacific market with USD 207.3 million revenue in 2017 and will grow considerably over the analysis timeframe. The growth is attributable to increasing demand for vaccines and monoclonal antibodies for treatment of numerous chronic diseases. Technological developments in biotechnology industry will fuel the demand for cell cultures thereby driving business growth. Increasing healthcare expenditure coupled with growing demand for advanced treatments will further accelerate the regional growth.

Key industry players operating in Asia Pacific cell line development market are GE Healthcare, Thermo Fisher Scientific, Lonza Group, Sigma-Aldrich Corporation (Merck), WuXi AppTec, Sartorius, Corning, Selexis, EuBiologics, Patheon, Samsung Biologics, GVK BIO, Progenitor Cell Therapy (PCT), and Abzena. Industry players are focusing on strategic partnerships, mergers, acquisitions and new product launch to enhance existing product portfolio and capitalize on market opportunities.

Segments We Cover:

Asia Pacific Cell Line Development Market, By Product

  • Reagents and media

  • Equipment

  • Accessories

Asia Pacific Cell Line Development Market, By Source

  • Mammalian

  • Non-mammalian

Asia Pacific Cell Line Development Market, By Cell Line Type

  • Recombinant cell lines

  • Hybridomas

  • Continuous cell lines

  • Primary cell lines

Asia Pacific Cell Line Development Market, By Application

  • Bioproduction

  • Drug discovery

  • Toxicity testing

  • Tissue engineering

  • Research

The above information is provided for the following countries:

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Malaysia

  • Indonesia

  • Thailand

  • Singapore

  • Taiwan

  • Philippines

  • Vietnam